Confusion: acetaminophen dosing changes based on NO evidence in adults

Edward P Krenzelok, Mike A Royal, Edward P Krenzelok, Mike A Royal

Abstract

Acetaminophen (paracetamol) plays a vital role in American health care, with in excess of 25 billion doses being used annually as a nonprescription medication. Over 200 million acetaminophen-containing prescriptions, usually in combination with an opioid, are dispensed annually. While acetaminophen is recognized as a safe and effective analgesic and antipyretic, it is also associated with significant morbidity and mortality (hepatotoxicity) if doses in excess of the therapeutic amount are ingested inappropriately. The maximum daily therapeutic dose of 3900-4000 mg was established in separate actions in 1977 and 1988, respectively, via the Food and Drug Administration (FDA) monograph process for nonprescription medications. The FDA has conducted multiple advisory committee meetings to evaluate acetaminophen and its safety profile, and has suggested (but not mandated) a reduction in the maximum daily dosage from 3900-4000 mg to 3000-3250 mg. In 2011, McNeil, the producer of the Tylenol® brand of acetaminophen, voluntarily reduced the maximum daily dose of its 500 mg tablet product to 3000 mg/day, and it has pledged to change the labeling of its 325 mg/tablet product to reflect a maximum of 3250 mg/day. Generic manufacturers have not changed their dosing regimens and they have remained consistent with the established monograph dose. Therefore, confusion will be inevitable as both consumers and health care professionals try to determine the proper therapeutic dose of acetaminophen. Which is the correct dose of acetaminophen: 3000 mg if 500 mg tablets are used, 3250 mg with 325 mg tablets, or 3900 mg when 650 mg arthritis-strength products are used?

References

    1. Ganley C. Memorandum, January 15, 2002; an archeological review of the regulatory history of over-the-counter (OTC) single ingredient acetaminophen [online]. Available from URL: [Accessed 2012 Jan 25].
    1. Drug Safety and Risk Management Advisory Committee. Acetaminophen: background and overview [online]. Available from URL: [Accessed 2012 Feb 21].
    1. Department of Health and Human Services, Food and Drug Administration. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; proposed amendment of the tentative final monograph; required warnings and other labeling. Fed Regist 2006; 71:77314–52 [online]. Available from URL: [Accessed 2012 Apr 3].
    1. Davidson D.G.D., Eastham W.N. Acute liver necrosis following overdose of paracetamol. Br Med J. 1966;2:497–9. doi: 10.1136/bmj.2.5512.497.
    1. Larson A.M., Polson J., Fontana R.J., et al. Acetaminopheninduced acute liver failure: results of a United States multicenter, prospective study. Hepatol. 2005;42:1364–72. doi: 10.1002/hep.20948.
    1. Lee W.M. Acetaminophen-related acute liver failure in the United States. Hepatol Res. 2008;38(1):S3–8. doi: 10.1111/j.1872-034X.2008.00419.x.
    1. Khandelwal N., James L.P., Sanders C., et al. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatol. 2011;53:567–76. doi: 10.1002/hep.24060.
    1. Budnitz D.S., Lovegrove M.C., Crosby A.E. Emergency department visits for overdoses of acetaminophen-containing products. Am J Prev Med. 2011;40:585–92. doi: 10.1016/j.amepre.2011.02.026.
    1. Krenzelok E.P. The FDA Acetaminophen Advisory Committee meeting — what is the future of acetaminophen in the United States? The perspective of a committee member. Clin Toxicol. 2009;47:784–9. doi: 10.1080/15563650903232345.
    1. Whitcomb D.C., Block G.D. Association of acetaminophen hepatotoxicity with fasting and ethanol use [comment in JAMA 1994;272: 1866-7; author reply in JAMA 1995;274: 301] JAMA. 1994;272:1845–50. doi: 10.1001/jama.1994.03520230055038.
    1. den Hertog H.M., van der Worp H.B., van Gement H.M.A., et al. The Paracetamol (Acetaminophen) in Stroke (PAIS) trial: a multicentre, randomized, placebo-controlled, phase III trial. Lancet Neurol. 2009;8:434–40. doi: 10.1016/S1474-4422(09)70051-1.
    1. Temple A.R., Benson G.D., Zinsenheim J.R., et al. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6–12 months) safety of acetaminophen in adult patients with osteoarthritis. Clin Ther. 2006;28:222–35. doi: 10.1016/j.clinthera.2006.02.004.
    1. Jones V.M. Acetaminophen injection: a review of clinical information. J Pain Palliative Care Pharmacother. 2011;25:340–9. doi: 10.3109/15360288.2011.606293.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj